Kang Stem Biotech Co., Ltd.
17
1
1
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 17 trials
100.0%
+13.5% vs industry average
12%
2 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Long-Term Follow-up Study of Subjects With Knee Osteoarthritis Who Had Administered FURESTEM-OA Kit Inj. in K0701 Study
Role: lead
Evaluate Safety and Explore Efficacy of FURESTEM-OA Kit Inj. in Patients With Knee Osteoarthritis
Role: lead
Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj(K0202)
Role: lead
Safety and Efficacy of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis
Role: lead
Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis
Role: lead
Safety and Efficacy of FURESTEM-AD Inj. for Moderate to Severe Atopic Dermatitis (AD)
Role: lead
Evalution the Safety and Efficacy in Atopic Dermatitis Patients
Role: lead
Long-term Follow-up Study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj
Role: lead
Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderate to Severe Chronic Atopic Dermatitis(AD)
Role: lead
Administration for Placebo Group and Evalution the Safety and Efficacy in Atopic Dermatitis Patients
Role: lead
Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis
Role: lead
Long-term Observational Study to Evalution the Safety and Efficacy of FURESTEM-AD Inj.
Role: lead
Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj
Role: lead
Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)
Role: lead
Long-term Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)
Role: lead
Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis(RA)
Role: lead
Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD)
Role: lead
All 17 trials loaded